| Name | Title | Contact Details |
|---|
Commerzbank AG is a prominent German financial institution founded in 1870 in Hamburg. It has grown to become one of Germanys leading commercial banks, significantly contributing to the countrys economic development. The bank is headquartered in Frankfurt am Main, with around 400 branches across Germany and international locations in cities like New York, Singapore, and London. Commerzbank offers a wide range of financial services for both private and corporate clients. For individuals and businesses, it provides payment solutions, securities trading, investment products, and financing options, including real estate and corporate loans. The bank is known for its free checking account offer. For corporate clients, Commerzbank delivers tailored banking products, capital structuring assistance, and support for international business activities, including foreign exchange services. Additionally, it offers green mortgage loans focused on energy efficiency. Commerzbank plays a vital role in financing German foreign trade, supporting a significant portion of the countrys international trade activities.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.